"Neumora’s Alzheimer’s disease agitation drug shows early success in Phase Ib trial" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

Before the advent of the amyloid hypothesis in the 1990s, the cholinergic hypothesis offered key clues to the etiology of Alzheimer’s disease. Concentrated in the basal forebrain and projecting ...

Researchers at Rutgers Robert Wood Johnson Medical School in New Brunswick are enrolling participants in the National ...

TOLEDO — The Alzheimer's Association Northwest Ohio Chapter is hosting several free programs in September. Events include "The Impact of Alzheimer’s and Dementia in our Community" at 5:30 p.m. Sept.

A new study led by researchers at UTHealth Houston investigated both gene expression and regulation at single cell levels to reveal disruptions in gene function in three brain regions of patients with ...

Spikes in blood sugar after eating may be more dangerous for the brain than previously thought. In a massive genetic study, ...

While the country faces an ongoing physician shortage, the nationwide neurologist shortage is even greater. Given the needs ...

A newly developed blood test for Alzheimer's disease not only aids in the diagnosis of the neurodegenerative condition but also indicates how far it has progressed, according to a new study. A newly ...

BILLERICA, Mass.--(BUSINESS WIRE)--Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), has introduced LucentAD Complete, a new multi-marker blood test designed to help detect ...

Alzheimer’s disease is a significant health challenge in Canada, affecting a growing number of individuals as the population ...